文献速递瓣膜外科

低危患者孤立性TAVR与SAVR五年结局比较

Isolated Transcatheter and Surgical Aortic Valve Replacement in the Evolut Low-Risk Trial: 5-Year Comparative Outcomes.
PubMed 文献 · Ann Thorac Surg · 2026-04-15

基于Evolut低危试验的事后分析,比较孤立性经导管主动脉瓣置换(TAVR)与外科主动脉瓣置换(SAVR)的5年结局。共纳入1164例患者(TAVR 667例,SAVR 497例),两组全因死亡或致残性卒中复合终点相似(15.5% vs 14.6%,P=84),TAVR组新永久起搏器植入率更高(27.3% vs 8.9%,P<.001)。

要点

  • 孤立性TAVR与SAVR的5年全因死亡或致残性卒中复合终点无显著差异。
  • TAVR组新永久起搏器植入率显著高于SAVR组(27.3% vs 8.9%)。
  • 两组5年主动脉瓣再干预率及中重度瓣周反流率均低且无显著差异。

核心结论

  • 在精心选择的低危孤立性主动脉瓣置换患者中,TAVR与SAVR的5年全因死亡、再干预及中重度瓣周反流率相似,支持TAVR作为合适治疗选择。

研究设计与样本

  • Evolut低危试验的事后分析,排除合并手术及交叉治疗患者后,纳入1164例(TAVR 667例,SAVR 497例),报告5年临床与超声结局。

主要发现

  • 5年全因死亡或致残性卒中复合终点:TAVR 15.5%,SAVR 14.6%(P=84)。
  • 5年全因死亡:TAVR 13.5%,SAVR 12.8%(P=85);心血管死亡:TAVR 6.9%,SAVR 8.3%(P=36)。
  • 新永久起搏器植入:TAVR 27.3%,SAVR 8.9%(P<.001)。
  • 5年主动脉瓣再干预率:TAVR 3.0%,SAVR 2.2%(P=51)。
  • 5年中重度瓣周反流:TAVR 0.5%,SAVR 0%(P=52)。

临床怎么用

  • 对于低危孤立性主动脉瓣置换患者,TAVR可作为SAVR的替代选择,但需权衡起搏器植入风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study aimed to compare the 5-year outcomes of patients who underwent isolated transcatheter aortic valve replacement (TAVR) vs patients who underwent isolated surgical aortic valve replacement (SAVR) from the Evolut Low Risk trial. METHODS: In the Evolut Low Risk trial, 1414 low-risk patients with severe aortic stenosis underwent TAVR using a self-expanding, supraannular CoreValve, Evolut R, or PRO bioprosthesis (Medtronic) or SAVR. This post hoc analysis excluded 250 patients, those with concomitant procedures (eg, percutaneous coronary intervention and coronary artery bypass grafting) and those who experienced crossover between treatment arms. The 5-year clinical and echocardiographic outcomes are reported. RESULTS: A total of 1164 patients underwent an isolated procedure (667 TAVR, 497 SAVR). At 5 years, the composite of all-cause mortality or disabling stroke was similar between the isolated groups (15.5% TAVR, 14.6% SAVR; P = .84). All-cause mortality (13.5% TAVR, 12.8% SAVR; P = .85) and cardiovascular mortality (6.9% TAVR, 8.3% SAVR; P = .36) were also comparable. New permanent pacemaker implantation was higher with TAVR (27.3% vs 8.9%; P < .001). The 5-year rate of aortic valve reintervention was 3.0% for TAVR and 2.2% for SAVR (P = .51). Moderate or greater paravalvular regurgitation occurred in 0.5% of TAVR patients and none of the SAVR patients (P = .52) at 5 years. CONCLUSIONS: This post hoc analysis of the Evolut Low Risk trial in patients undergoing isolated TAVR or SAVR demonstrates similar rates of all-cause mortality, reintervention, and moderate or greater paravalvular regurgitation at 5 years, supporting Evolut TAVR as a suitable treatment option in carefully selected low-risk patients undergoing isolated valve replacement.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Ramlawi B, Deeb GM, Yakubov SJ, et al. Isolated Transcatheter and Surgical Aortic Valve Replacement in the Evolut Low-Risk Trial: 5-Year Comparative Outcomes. Ann Thorac Surg. 2026. PMID: 41997523. doi:10.1016/j.athoracsur.2026.03.070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。